Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Stegmayr B) > Adverse events and ...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		03355naa a2200397 4500
001		oai:DiVA.org:liu-47223
003		SwePub
008		091011s2001 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-472232 URI
024	7	a https://doi.org/10.1016/S1473-0502(01)00079-92 DOI
040		a (SwePub)liu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Norda, R.u Department of Transfusion Medicine and Immunohemotherapy, Örebro Medical Center Hospital, SE 701 85 Örebro, Sweden4 aut
245	1 0	a Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry
264	1	c 2001
338		a print2 rdacarrier
520		a Background: Since 1996 adverse events (AE) in therapeutic apheresis (TA) have been more extensively registered in Sweden. This report analyzes the extent and relation of AEs to procedures and diagnoses. Materials and methods: Reporting of TA performed in Sweden was centralized. A separate system for the registration of AE in TA was established and the data received were entered into a central database for registration and analyses. Fifteen of all 35 apheresis units reported both TA and AE during 1996-1999. These centers performed 75% of all TA procedures. Adverse events included medical symptoms, vascular access problems, technical and other problems. Results: More than 14,000 procedures were registered during the observation period. No fatalities occurred. AEs occurred in 3.7% (1996), 4.6% (1997), 4.2% (1998) and 4.4% (1999) of procedures. Interventions during the adverse event were performed in about 65% of the events. Apheresis procedures were interrupted due to an adverse event in about 1%. Adverse events occurred in 5.6% of plasma exchanges, 1.9% of plasma modulations and 6.8% of cytapheresis procedures. Paresthesia was registered in 22% and hypotensive events in 20.5%. Other more frequent symptoms were urticaria (14.4%), shivering (7.4%) and nausea (7.4%). AEs were most frequent in patients with Goodpasture's syndrome (12.5%), TTP/HUS (10.5%) and GuillainBarré syndrome (11.0%). Conclusion: AEs are few, often mild and less common in plasma modulation than plasma exchange. AEs are more frequent during TA of patients with certain diagnoses such as TTP/HUS. Copyright © 2001 Elsevier Science Ltd.
653		a Adverse events
653		a Apheresis
653		a Hematopoietic progenitor cell collection
653		a Immunoadsorption
653		a National registry
653		a Photopheresis
653		a Plasma exchange
653		a Plasmapheresis
653		a NATURAL SCIENCES
653		a NATURVETENSKAP
700	1	a Berseus, O.4 aut
700	1	a Stegmayr, B.u Department of Internal Medicine, Division of Nephrology, University Hospital, Umeå, Sweden4 aut
710	2	a Department of Transfusion Medicine and Immunohemotherapy, Örebro Medical Center Hospital, SE 701 85 Örebro, Swedenb Department of Internal Medicine, Division of Nephrology, University Hospital, Umeå, Sweden4 org
773	0	t Transfusion and apheresis scienceg 25:1, s. 33-41q 25:1<33-41x 1473-0502x 1878-1683
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-47223
856	4 8	u https://doi.org/10.1016/S1473-0502(01)00079-9

Hitta via bibliotek

Transfusion and apheresis science (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Norda, R.; Berseus, O.; Stegmayr, B.

Artiklar i publikationen: Transfusion and ...

Av lärosätet: Linköpings universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se